Fort Washington Investment Advisors Inc. OH Increases Holdings in Progyny, Inc. $PGNY

Fort Washington Investment Advisors Inc. OH boosted its stake in Progyny, Inc. (NASDAQ:PGNY) by 46.9% in the 1st quarter, Holdings Channel reports. The firm owned 2,693,393 shares of the company’s stock after buying an additional 859,289 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Progyny were worth $45,734,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in PGNY. California State Teachers Retirement System lifted its stake in shares of Progyny by 0.7% during the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after purchasing an additional 457 shares in the last quarter. Teza Capital Management LLC grew its stake in shares of Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after buying an additional 516 shares in the last quarter. Leibman Financial Services Inc. grew its stake in shares of Progyny by 1.2% in the fourth quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock valued at $1,192,000 after buying an additional 528 shares in the last quarter. Aristides Capital LLC raised its holdings in shares of Progyny by 4.6% during the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after buying an additional 528 shares during the period. Finally, Oxford Asset Management LLP lifted its position in Progyny by 4.3% during the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock worth $284,000 after acquiring an additional 531 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on PGNY. BTIG Research decreased their price target on Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Jefferies Financial Group reiterated a “buy” rating and set a $30.00 price objective on shares of Progyny in a research note on Friday, March 6th. Citizens Jmp upped their target price on shares of Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research note on Monday, May 11th. Wall Street Zen upgraded shares of Progyny from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Weiss Ratings raised shares of Progyny from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Progyny presently has a consensus rating of “Moderate Buy” and an average price target of $29.92.

Insider Activity at Progyny

In other news, insider Geoffrey Clapp sold 1,530 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the sale, the insider owned 59,117 shares of the company’s stock, valued at approximately $1,512,212.86. This trade represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kevin K. Gordon sold 5,500 shares of Progyny stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total transaction of $137,445.00. Following the completion of the sale, the director owned 9,318 shares of the company’s stock, valued at approximately $232,856.82. This trade represents a 37.12% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 36,916 shares of company stock worth $939,875. 9.90% of the stock is currently owned by insiders.

Progyny Stock Performance

NASDAQ:PGNY opened at $28.51 on Friday. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of 37.03, a price-to-earnings-growth ratio of 2.52 and a beta of 1.03. Progyny, Inc. has a one year low of $16.10 and a one year high of $28.75. The business’s 50-day simple moving average is $23.45 and its 200 day simple moving average is $22.39.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm had revenue of $328.50 million during the quarter, compared to analyst estimates of $326.46 million. During the same quarter last year, the firm earned $0.17 EPS. Progyny’s quarterly revenue was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, equities research analysts predict that Progyny, Inc. will post 1.07 EPS for the current year.

Progyny announced that its board has authorized a stock buyback program on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 10.3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.